arrow Log In to View Account     |          

Tuesday, October 2nd at 9:00 PM ET

Presenters: Ali McBride, PharmD, MS, BCPS, BCOP,
and John Valgus, PharmD, BCOP, CPP

This webcast will provide live credit (L) for those states requiring it.

Earn 1.5 contact hours of live (L) credit!

Biosimilar drugs offer the potential to foster significant improvements in patient management by substantially reducing healthcare costs and increasing patient access to potentially life-saving therapies. However, their use remains clouded by clinician uncertainty regarding their efficacy, safety, and how they appropriately fit into clinical practice, precluding patients from reaping these benefits. While mimicking the concept of generic small molecule drugs and their branded agents, the association between biosimilars and their reference biological products is more complex, requiring unique considerations for development and regulatory approval. In this activity, we will review key differences between biosimilars, generics, and reference biologics; US Food and Drug Administration (FDA) regulatory requirements for their approval and interchangeability; their importance as a key component of value-based care; and, pharmacist-led strategies to overcome administrative and educational barriers to biosimilar implementation.

The goal of this educational activity is to understand the unique considerations in treating patients with biosimilars as part of the provision of value-based care, as well as to develop pharmacist-driven strategies for optimizing the use of biosimilars in clinical practice.

This activity is primarily intended for pharmacists from all practice settings (eg, specialty, managed care, community/retail, health-systems, and other settings). No prerequisites required.

  • Activity Overview and Goals
    Ali McBride, PharmD, MS, BCPS, BCOP
  • The Future of Value-Based Care: An Introduction to Biosimilars
    John Valgus, PharmD, BCOP, CPP
  • Question and Answer Session Part 1
    Faculty Panel
  • Practice Implications of Biosimilars: Perspectives for Pharmacists
    Ali McBride, PharmD, MS, BCPS, BCOP
  • Clinical Pearls for Reimbursement and Coverage of Biosimilars
    Ali McBride, PharmD, MS, BCPS, BCOP
  • Question and Answer Session Part 2
    Faculty Panel
  • Conclusions and Postassessment
    Ali McBride, PharmD, MS, BCPS, BCOP
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:
  • DIFFERENTIATE biosimilars and the regulatory processes involved in biosimilar approval from their reference products and from generics of small molecule drugs.
  • EVALUATE biosimilars as a key component of the value-based care paradigm, as well as their role in current practice models.
  • DEVELOP strategies for patient and healthcare provider education on the potential advantages of biosimilars.
  • DESIGN strategies, including appropriate documentation and coding, to facilitate reimbursement of biosimilars.
Ali McBride, PharmD, MS, BCPS, BCOP (Course Director)
Clinical Coordinator
Hematology/Oncology Department of Pharmacy
University of Arizona Cancer Center
Tucson, Arizona

John Valgus, PharmD, BCOP, CPP
Assistant Professor of Clinical Education
UNC Eshelman School of Pharmacy
UNC School of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.

acpe logoThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based activity will provide a statement for 1.5 live contact hours of credit (0.15 CEUs) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the educational activity; 3) completing the self-assessment instrument with a score of at least 70%. UAN: 0064-0000-18-206-L04-P. CE credit will be submitted to the NABP CPE Monitor within 30 days. It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website:
To receive credit for your participation in this activity, all pharmacists must include their CORRECT NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE-Monitor.

It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the presentations.

A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or coprovided by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

Operating System: Windows 98 or higher & Macintosh 2.2 or higher
Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.
Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible

There is no fee for this educational activity.

<img src="" alt="procced to pretest" border="0" />
University of Tennessee Advanced Studies in Pharmacy (ISSN-1558-0350), is published by ASiM CE, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC.